FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)(FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)) - 药物靶点：SARS-CoV-2 S protein_在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、重组亚单位疫苗

别名

靶点

SARS-CoV-2 S protein

作用机制

SARS-CoV-2 S protein调节剂(冠状病毒刺突糖蛋白调节剂)

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

Finlay Vaccine Institute

在研机构

Finlay Vaccine Institute

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的临床试验

RPCEC00000384 / Recruiting临床2期IIT

Exploratory and open study, to evaluate the safety, reactogenicity and immunogenicity, of a heterologous scheme of two doses of the prophylactic anti SARS vaccine candidate - CoV - 2, FINLAY-FR-2 and one dose of FINLAY-FR-1A, in Cuban children and adolescents (COVID-19) - SOBERANA PEDIATRIA CLINICA 1

开始日期2021-07-17

申办/合作机构-

RPCEC00000354 / Completed临床3期IIT

Phase III clinical trial, multicenter, adaptive, parallel-group, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and immunogenicity of vaccination against SARS-CoV-2 with 2 doses of FINLAY-FR-2 and a heterologous scheme with 2 doses of FINLAY-FR-2 and a booster dose with FINLAY-FR-1A (COVID-19) - SOBERANA 02-Fase III

开始日期2021-03-08

申办/合作机构

Finlay Vaccine Institute

RPCEC00000340 / Completed临床1期IIT

Phase I study, open, sequential and adaptive for evaluating the safety, reactogenicity and explore the immunogenicity of the prophylactic Vaccine Candidate FINLAY-FR-2 anti SARS-CoV-2 (COVID-19) - SOBERANA 02

开始日期2020-11-02

申办/合作机构

Finlay Vaccine Institute

100 项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的临床结果

登录后查看更多信息

100 项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的转化医学

登录后查看更多信息

100 项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的专利（医药）

登录后查看更多信息

103

项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的文献（医药）

2024-11-01·Journal of the American Medical Directors Association

Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study

Article

作者: Coin, Alessandra ; Okoye, Chukwuma ; Zazzara, Maria Beatrice ; Del Signore, Susanna ; Malara, Alba ; Incalzi, Raffaele Antonelli ; Trevisan, Caterina ; Abbatecola, Angela Marie ; Onder, Graziano ; Palmieri, Annapina ; Timmons, Suzanne ; Ceolin, Chiara ; Fedele, Giorgio ; Bellelli, Giuseppe ; Prato, Rosa ; Fortunato, Francesca

OBJECTIVESARS-CoV-2 vaccination can bring an important benefit for older people in terms of reduction of mortality and hospitalization; however, reports of rare adverse effects like altered consciousness and delirium among this demographic have raised concerns. This study aimed to assess delirium incidence post-SARS-CoV-2 vaccination and its predictors in older residents across 60 Italian long-term care facilities (LTCFs).DESIGNThis is a prospective cohort study considering data from GeroCovid Vax, a multicenter cohort study jointly performed by the Italian Society of Gerontology and Geriatrics (SIGG) (Florence, Italy) and the Italian National Institute of Health (Istituto Superiore di Sanità-ISS, Rome, Italy), and sponsored by the Italian Medicines Agency (Agenzia Italiana del Farmaco-AIFA).SETTING AND PARTICIPANTSGeroCovid Vax enrolled LTCFs residents aged ≥60 who received at least 1 anti-SARS-CoV-2 vaccine dose.METHODSBaseline data covered sociodemographic details, chronic diseases, medications, nutritional status, cognitive and functional assessments, mobility, and frailty. Delirium was assessed post-first, second, and booster vaccine doses using DSM-5 criteria. Data analysis involved descriptive statistics, multivariate logistic regression, and network analysis.RESULTSA total of 2521 participants (mean age 83.10 ± 9.21 years, 70.7% female) were analyzed. Delirium incidence post-first, second, and booster doses was 3.5%, 1.6%, and 1.5%, respectively. Age, preexisting cognitive disorders, and frailty were significant predictors of delirium, with odds ratios (ORs) of 1.70 (95% CI, 1.08-2.77), 2.05 (95% CI, 1.40-2.97), and 1.77 (95% CI, 1.25-2.52), respectively. Prior use of antipsychotics (OR, 1.75; 95% CI, 1.22-2.51) and antidepressants (OR, 1.77; 95% CI, 1.25-2.52) correlated significantly with delirium. Network analysis indicated a strong association between anorexia and delirium.CONCLUSION AND IMPLICATIONSPost-vaccination delirium is infrequent and decreases with subsequent doses. Timely assessments for frailty and cognitive impairment could aid in stratifying delirium risk among LTCF residents, facilitating enhanced prevention measures and close monitoring for delirium indicators.

2024-03-01·Journal of the European Academy of Dermatology and Venereology

PsoBioVax: A multicentric Italian case–control study of the immunological response to anti‐SARS‐CoV‐2 vaccine among psoriatic patients under biological therapy

Letter

作者: Esposito, M ; Corazza, M ; Bellinato, F ; Gisondi, P ; Burlando, M ; Campanati, A ; Bardazzi, F ; Diotallevi, F ; Potenza, C ; Stingeni, L ; Filippi, F ; Odorici, G ; Satolli, F ; Di Lernia, V ; Giunta, A ; Chessa, M A ; Balestri, R ; Gibertoni, D ; Ruggiero, A ; Rech, G ; Megna, M ; Rovesti, M ; Bernardini, N ; Hansel, K ; Sacchelli, L ; Fargnoli, M C ; Prignano, F ; Di Cesare, A ; Bianchi, L ; Magnano, M ; Balato, A

2024-01-01·Journal of Medical Virology

Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID‐19: A systematic review and meta‐analysis

Review

作者: Scovenna, Francesco ; Carlini, Valentina ; Tanzi, Elisabetta ; La Sala, Lucia ; Martin-Delgado, Jimmy ; Pontiroli, Antonio E ; Zanoni, Ivan ; Tagliabue, Elena

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) causes COVID‐19 and has brought a huge burden in terms of human lives. Strict social distance and influenza vaccination have been recommended to avoid co‐infections between influenza viruses and SARS‐CoV‐2. Scattered reports suggested a protective effect of influenza vaccine on COVID‐19 development and severity. We analyzed 51 studies on the capacity of influenza vaccination to affect infection with SARS‐CoV‐2, hospitalization, admission to Intensive Care Units (ICU), and mortality. All subjects taken into consideration did not receive any anti‐SARS‐CoV‐2 vaccine, although their status with respect to previous infections with SARS‐CoV‐2 is not known. Comparison between vaccinated and not‐vaccinated subjects for each of the four endpoints was expressed as odds ratio (OR), with 95% confidence intervals (CIs); all analyses were performed by DerSimonian and Laird model, and Hartung‐Knapp model when studies were less than 10. In a total of 61 029 936 subjects from 33 studies, influenza vaccination reduced frequency of SARS‐CoV‐2 infection [OR plus 95% CI = 0.70 (0.65−0.77)]. The effect was significant in all studies together, in health care workers and in the general population; distance from influenza vaccination and the type of vaccine were also of importance. In 98 174 subjects from 11 studies, frequency of ICU admission was reduced with influenza vaccination [OR (95% CI) = 0.71 (0.54−0.94)]; the effect was significant in all studies together, in pregnant women and in hospitalized subjects. In contrast, in 4 737 328 subjects from 14 studies hospitalization was not modified [OR (95% CI) = 1.05 (0.82−1.35)], and in 4 139 660 subjects from 19 studies, mortality was not modified [OR (95% CI) = 0.76 (0.26−2.20)]. Our study emphasizes the importance of influenza vaccination in the protection against SARS‐CoV‐2 infection.

100 项与 FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) 相关的药物交易

登录后查看更多信息